Procyrion, inc.

Procyrion, Inc. is a medical device company that has developed an innovative circulatory assist device called Aortix™. This catheter-deployed device is designed to help millions of heart failure patients who are too sick for medication alone.

Heart failure is a serious condition that affects millions of people worldwide. It occurs when the heart cannot pump enough blood to meet the body's needs, leading to symptoms such as shortness of breath, fatigue, and swelling in the legs and ankles. While medications can help manage these symptoms, they do not address the underlying problem of poor blood flow.

This is where Procyrion's Aortix™ comes in. This tiny device is inserted into the patient's aorta via a catheter and sits just below the heart. It works by creating a gentle suction force that helps draw blood out of the heart and into circulation throughout the body.

One of the key benefits of Aortix™ is its minimally invasive nature. Unlike other circulatory assist devices that require open-heart surgery or implantation under general anesthesia, Aortix™ can be inserted using only local anesthesia and conscious sedation.

Another advantage of Aortix™ is its small size - it measures just 6mm in diameter and 6cm in length - making it suitable for patients with smaller arteries or those who have already undergone multiple surgeries.

But perhaps most importantly, clinical trials have shown that Aortix™ can significantly improve patients' quality of life by reducing symptoms such as shortness of breath and fatigue while also improving their exercise capacity.

Procyrion was founded in 2005 by Drs. Reynolds Delgado III and William Cohn with a mission to develop innovative medical devices that improve patient outcomes while reducing healthcare costs. Since then, they have raised over $30 million in funding from investors including Fannin Innovation Studio, Scientific Health Development Group (SHDG), Targeted Technology Fund II (TTF II), Houston Angel Network (HAN), Cowtown Angels among others

The company has also received numerous awards for its groundbreaking technology including being named one among "Houston’s Most Innovative Companies" by Houston Business Journal; "Top Ten Cardiovascular Device Companies" by MedTech Outlook; "Top Ten Medical Device Startups" at The MedTech Conference; "Best Cardiovascular Innovation Award" at TCT Connect 2020 among others

In addition to developing Aortix™ for heart failure patients, Procyrion has also been exploring other potential applications for its technology such as improving blood flow during dialysis or preventing complications after surgery.

Overall Procyrion's innovative approach towards developing minimally invasive medical devices like AortixTM shows great promise towards revolutionizing cardiovascular care globally while providing better outcomes at lower costs than traditional methods currently available on market today